Evidence map›Paper›PMID 31034006›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Despite Predominance of Uropathogenic/Extraintestinal Pathotypes Among Travel-acquired Extended-spectrum β-Lactamase-producing Escherichia coli, the Most Commonly Associated Clinical Manifestation Is Travelers' Diarrhea.

Anu Kantele, Tinja Lääveri, Sointu Mero, Inka M K Häkkinen, Juha Kirveskari, Brian D Johnston, James R Johnson

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Dominance ofMicrobial genomics · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Import of multidrug-resistant bacteria from abroad through interhospital transfers, Finland, 2010-2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Observational
  11. Article
  12. Review
  13. Multidrug-Resistant Lineage of EnterotoxigenicFrontiers in microbiology · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Anu KanteleInflammation Center, Infectious Diseases, Helsinki University Hospital and University of Helsinki, Finland.
Tinja LääveriInflammation Center, Infectious Diseases, Helsinki University Hospital and University of Helsinki, Finland.
Sointu MeroHelsinki University Hospital Laboratory, Bacteriology, Finland.
Inka M K HäkkinenInflammation Center, Infectious Diseases, Helsinki University Hospital and University of Helsinki, Finland.
Juha KirveskariHelsinki University Hospital Laboratory, Bacteriology, Finland.
Brian D JohnstonInfectious Diseases, Veterans Affairs Medical Center, Minneapolis, Minnesota.
James R JohnsonInfectious Diseases, Veterans Affairs Medical Center, Minneapolis, Minnesota.
Helsinki University Hospital · FIUniversity of Helsinki · FIVeterans Health Administration · USAava Medical Centre · FI

Funding

CSRD VA I01 CX000920
6 · The paper itself

Abstract

backgroundOne-third of the 100 million travelers to the tropics annually acquire extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE), with undefined clinical consequences.

methodsSymptoms suggesting Enterobacteriaceae infections were recorded prospectively among 430 Finnish travelers, 90 (21%) of whom acquired ESBL-PE abroad. ESBL-PE isolates underwent polymerase chain reaction-based detection of diarrheagenic Escherichia coli (DEC) pathotypes (enteroaggregative E. coli [EAEC], enteropathogenic E. coli [EPEC], enterotoxigenic E. coli [ETEC], enteroinvasive E. coli, and Shiga toxin-producing E. coli), and extraintestinal pathogenic/uropathogenic E. coli (ExPEC/UPEC). Laboratory-confirmed ESBL-PE infections were surveyed 5 years before and after travel.

resultsAmong the 90 ESBL-PE carriers, manifestations of Enterobacteriaceae infection included travelers' diarrhea (TD) (75/90 subjects) and urinary tract infection (UTI) (3/90). The carriers had 96 ESBL-producing E. coli isolates, 51% exhibiting a molecular pathotype: 13 (14%) were DEC (10 EAEC, 2 EPEC, 1 ETEC) (12 associated with TD) and 39 (41%) ExPEC/UPEC (none associated with UTI). Of ESBL-PE, 3 (3%) were ExPEC/UPEC-EAEC hybrids (2 associated with diarrhea, none with UTI). Potential ESBL-PE infections were detected in 15 of 90 subjects (17%). The 10-year medical record survey identified 4 laboratory-confirmed ESBL-PE infections among the 430 travelers, all in subjects who screened ESBL-PE negative after returning home from their index journeys but had traveled abroad before their infection episodes.

conclusionsHalf of all travel-acquired ESBL-producing E. coli strains qualified molecularly as pathogens. Extraintestinal and uropathogenic pathotypes outnumbered enteric pathotypes (41% vs 14%), yet the latter correlated more closely with symptomatic infection (0% vs 92%). Despite more ESBL-PE strains qualifying as ExPEC/UPEC than DEC, travel-acquired ESBL-PE are more often associated with TD than UTI.

Indexed as

Enteropathogenic Escherichia coliEscherichia coli Infectionsbeta-LactamasesDiarrheaFecesHumansTravelbeta-LactamasesDECESBLExPECextended-spectrum beta-lactamasetravel

Identifiers

PMID31034006
PMCPMC6938974
OpenAlexW2943455343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.